文献速递造血干细胞移植与细胞治疗白血病MDS 与骨髓增殖性肿瘤

无需供者淋巴细胞输注的持久移植物抗白血病效应——序贯T细胞充足异基因移植治疗高危急性髓系白血病和骨髓增生异常综合征的II期研究结果

Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia.
PubMed 文献 · Br J Haematol · 2017-10-26

该单臂前瞻性II期试验纳入47例复发/难治急性髓系白血病或高危骨髓增生异常综合征患者,43例接受序贯化疗后T细胞充足减低强度预处理移植、不计划供者淋巴细胞输注。移植患者1年和3年总生存率分别为45%和33%,仅1例发生巨细胞病毒病,1年治疗相关死亡和复发累积发生率分别为35%和20%。

要点

  • 序贯T细胞充足减低强度预处理移植可不依赖供者淋巴细胞输注自发获得高供者嵌合。
  • 移植患者1年和3年总生存率分别为45%和33%,仅1例发生巨细胞病毒病。
  • 1年治疗相关死亡和复发累积发生率分别为35%和20%,晚发性移植物抗宿主病与复发保护相关。

核心结论

  • 序贯T细胞充足减低强度预处理移植对复发/难治急性髓系白血病和骨髓增生异常综合征可行,且无需供者淋巴细胞输注即可产生移植物抗白血病效应。

研究设计与样本

  • 单臂前瞻性II期临床试验,纳入47例复发/难治急性髓系白血病或高危骨髓增生异常综合征患者,43例接受序贯化疗后T细胞充足减低强度预处理移植、不计划供者淋巴细胞输注,主要终点为总生存。

主要发现

  • 移植患者1年和3年总生存率分别为45%和33%。
  • 无需供者淋巴细胞输注即自发达到高供者嵌合水平。
  • 仅1例患者发生巨细胞病毒病。
  • 1年治疗相关死亡累积发生率为35%,1年复发累积发生率为20%。
  • 复发急性髓系白血病和骨髓增生异常综合征患者结局最好,晚发性移植物抗宿主病对复发有保护作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Allogeneic haematopoietic stem-cell transplantation remains the only curative treatment for relapsed/refractory acute myeloid leukaemia (AML) and high-risk myelodysplasia but has previously been limited to patients who achieve remission before transplant. New sequential approaches employing T-cell depleted transplantation directly after chemotherapy show promise but are burdened by viral infection and require donor lymphocyte infusions (DLI) to augment donor chimerism and graft-versus-leukaemia effects. T-replete transplantation in sequential approaches could reduce both viral infection and DLI usage. We therefore performed a single-arm prospective Phase II clinical trial of sequential chemotherapy and T-replete transplantation using reduced-intensity conditioning without planned DLI. The primary endpoint was overall survival. Forty-seven patients with relapsed/refractory AML or high-risk myelodysplasia were enrolled; 43 proceeded to transplantation. High levels of donor chimerism were achieved spontaneously with no DLI. Overall survival of transplanted patients was 45% and 33% at 1 and 3 years. Only one patient developed cytomegalovirus disease. Cumulative incidences of treatment-related mortality and relapse were 35% and 20% at 1 year. Patients with relapsed AML and myelodysplasia had the most favourable outcomes. Late-onset graft-versus-host disease protected against relapse. In conclusion, a T-replete sequential transplantation using reduced-intensity conditioning is feasible for relapsed/refractory AML and myelodysplasia and can deliver graft-versus-leukaemia effects without DLI.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Davies JK, Hassan S, Sarker SJ, et al. Durable graft-versus-leukaemia effects without donor lymphocyte infusions - results of a phase II study of sequential T-replete allogeneic transplantation for high-risk acute myeloid leukaemia and myelodysplasia. Br J Haematol. 2017. PMID: 29076145. doi:10.1111/bjh.14980

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。